HC Wainwright Reiterates Buy Rating for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $104.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 411.56% from the company’s current price.

Separately, StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research report on Friday, March 21st.

XOMA Price Performance

XOMA opened at $20.33 on Friday. XOMA has a twelve month low of $19.92 and a twelve month high of $35.00. The firm has a market cap of $243.53 million, a price-to-earnings ratio of -5.84 and a beta of 1.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The company has a fifty day simple moving average of $23.76 and a 200 day simple moving average of $26.90.

XOMA (NASDAQ:XOMA) last announced its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. Equities research analysts expect that XOMA will post -1.41 EPS for the current fiscal year.

Insider Activity at XOMA

In other news, CIO Bradley Sitko purchased 4,134 shares of the stock in a transaction dated Friday, March 21st. The stock was acquired at an average cost of $23.89 per share, for a total transaction of $98,761.26. Following the acquisition, the executive now owns 10,484 shares of the company’s stock, valued at $250,462.76. The trade was a 65.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The disclosure for this sale can be found here. Insiders bought a total of 4,747 shares of company stock valued at $114,544 over the last three months. 7.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets raised its stake in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares during the period. New York State Common Retirement Fund raised its position in shares of XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 800 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of XOMA by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,183 shares during the last quarter. Bank of America Corp DE boosted its position in XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 2,009 shares during the period. Finally, Los Angeles Capital Management LLC bought a new position in XOMA during the 4th quarter worth $206,000. 95.92% of the stock is owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.